Clinical Trial

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Protocol Amendment History 1 change
notable Trial sites expanded: 11 -> 14 locations 2026-05-06
Trial Details
NCT Number NCT07140900
Lead Sponsor Amgen
Conditions Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment 60 participants
Start Date 2025-10-07
Primary Completion 2028-03-27 (estimated)
Study Completion 2030-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02